Trial Profile

A Phase II, Randomized, Multicenter, Open-Label, Controlled Study of Tobemstomig Alone or in Combination With Tiragolumab Versus Atezolizumab in Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer Who Are Ineligible for Platinum-Containing Chemotherapy

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tiragolumab (Primary) ; Tobemstomig (Primary) ; Atezolizumab
Indications Bladder cancer; Carcinoma; Squamous cell cancer; Transitional cell carcinoma; Urogenital cancer
Focus Adverse reactions
Sponsors Roche

30 Jan 2026 Planned End Date changed from 20 Mar 2026 to 31 Dec 2026.
30 Jan 2026 Planned primary completion date changed from 20 Mar 2026 to 31 Dec 2026.
31 Oct 2025 Planned End Date changed from 30 Dec 2026 to 20 Mar 2026.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com